Radionuclide imaging studies in the assessment of nasal drug delivery in humans

American Journal of Drug Delivery

Volumn 2, Issue 2, 2004, Pages 101-112

  Newman, Stephen P ^a   Illum, Lisbeth ^b  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b IDentity   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUTORPHANOL; CALCITONIN; CARBON 11; CHITOSAN; CORTICOSTEROID; DECONGESTIVE AGENT; DESMOPRESSIN; ESTROGEN; FLUORINE 18; HUMAN SERUM ALBUMIN; HYDROXYPROPYLMETHYLCELLULOSE; INDIUM 111; INSULIN; IODINE 123; MICROSPHERE; MORPHINE; NOSE DROPS; PENTETATE TECHNETIUM TC 99M; PEPTIDE; POLITEF; PROTEIN; SUMATRIPTAN; TECHNETIUM 99M; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; ZANAMIVIR; ZOLMITRIPTAN;

AEROSOL; COMPUTER ASSISTED TOMOGRAPHY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG ADSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG TARGETING; DRY POWDER; FOOD AND DRUG ADMINISTRATION; GAMMA SCINTIGRAPHY; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LUNG PARENCHYMA; MEDICAL ASSESSMENT; METERED DOSE INHALER; MUCOCILIARY CLEARANCE; NEBULIZER; NOSE CAVITY; POSITRON EMISSION TOMOGRAPHY; POWDER INHALER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; UNITED STATES;

EID: 3242772975     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200402020-00003     Document Type: Review

References (84)

1. Mygind N, Weeke B. Allergic and vasomotor rhinitis: clinical aspects. Copenhagen: Munksgaard, 1985
2. Wilson CG, Washington N. Nasal drug delivery. In: Wilson CG, Washington N, editors. Physiological pharmaceutics: biological barriers to drug absorption. Chichester: Ellis Horwood, 1989: 139-54
3. Chien YW. Transnasal systemic medications. Amsterdam: Elsevier, 1985
4. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002; 7: 1184-9
5. Davis SS, Illum L. Nasal delivery of drugs, vaccines and DNA: a novel concept. Eur Pharm Contractor 2000; Aug: 54-8
6. Cheng Y-H, Watts P, Hinchcliffe M, et al. Development of a novel nasal formulation comprising an optimal pulsatile and sustained plasma profile for smoking cessation. J Control Release 2002; 79: 243-54
7. Harris AS. Clinical opportunities provided by the nasal administration of peptides. J Drug Target 1993; 1: 101-16
8. Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Release 2003; 87: 187-98
9. Jabbal-Gill I. Nasal vaccines. Drug Deliv Systems Sci 2001; 3: 89-94
10. Vajdy M, O'Hagan DT. Microparticles for intranasal immunization. Adv Drug Del Rev 2001; 51: 127-41
11. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 1: 1-18
12. Qurashi MS, Jones NS, Mason JDT. The nasal delivery of drugs. Clin Otolaryngol 1997; 22: 389-01
13. Lambert P. Nasal drug delivery: the powder advantage. Eur Pharm Contractor 2002; Summer: 66-9
14. Petri W, Schmiedel R, Sandow J. Development of a metered-dose nebulizer for intranasal peptide administration. In: Chien YW, editor. Transnasal systemic medications. Amsterdam: Elsevier Science Publishers, 1985: 161-81
15. Bommer R. Advances in nasal drug delivery technology. Pharm Tech Eur 1999; Sep: 26-33
16. Bruna P, Burel S, Carlotti P, et al. A comparative study of two single dose powder aerosol devices for delivery to the nasal airways. Proceedings of Drug Delivery to the Lungs X; 1999 Dec 2-3; London. Bristol: The Aerosol Society, 1999: 48-51
17. Nomura M, Yanagawa A, Okuno T, et al. A comparison of spray devices for intranasal peptide administration. Pharm Tech Eur 1998; Oct: 58
18. Mygind N. Upper airway: structure, function and therapy. In: Morén F, Dolovich MB, Newhouse MT, et al., editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier, 1993: 1-26
19. Heyder J, Gebhardt J, Rudolf G, et al. Deposition of particles in the human respiratory tract in the size range 0.005 to 15 μm. J Aerosol Sci 1986; 17: 811-25
20. Task Group on Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys 1966; 12: 173-207
21. Sakakura Y, Ukai K, Majima Y, et al. Nasal mucociliary clearance under various conditions. Acta Otolaryngol 1983; 96: 167-73
22. Anderson I, Proctor DF. Measurement of nasal mucociliary clearance. Eur J Respir Dis 1983; 64 Suppl. 127: 37-40
23. Proctor DF. Nasal physiology in intranasal drug administration. In: Chien YW, editor. Transnasal systemic medications. Amsterdam: Elsevier, 1985: 101-6
24. Proctor DF, Anderson I, Lundquist G. Clearance of inhaled particles from the human nose. Arch Intern Med 1973; 131: 132-9
25. Hounam RF. The removal of particles from the nasopharyngeal compartment of the respiratory tract by nose blowing and swabbing. Health Phys 1975; 28: 743-53
26. Fisher AN, Illum L, Davis SS, et al. Di-iodo-L-tyrosone labelled dextrans as molecular size markers of nasal absorption. J Pharm Pharmacol 1992; 44: 550-4
27. Schipper NGM, Verhoef JC, Merkus FWHM. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 1991; 8: 807-15
28. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994; 11: 1186-9
29. Cheng YS, Holmes TD, Gao J, et al. Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J Aerosol Med 2001; 14: 267-80
30. Hallworth GW, Padfield JM. A comparison of the regional deposition in a model nose of a drug discharged from metered aerosol and metered pump nasal delivery systems. J Allergy Clin Immunol 1986; 77: 348-53
31. Durand M, Rusch P, Granjon D, et al. Preliminary study of the deposition of aerosol in the maxillary sinuses using a plastinated model. J Aerosol Med 2001; 14: 83-93
32. Miyabe S, Koizuka I, Tanaka K, et al. Distribution of the fluticasone propionate aerosol particles in the nasal cavity during aerosol therapy. Sei Marianna Ika Daikagu Zasshi 1999; 27: 503-9
33. Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des 2000; 6: 1631-51
34. Davis SS, Hardy JG, Newman SP, et al. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med 1992; 19: 971-86
35. Meseguer G, Gurny R, Buri P. In vivo evaluation of dosage forms: application of gamma scintigraphy to non-enteral routes of administration. J Drug Target 1994; 2: 269-88
36. Smaldone GC. Radionuclide scanning, respiratory physiology and pharmacokinetics. J Aerosol Med 2001; 14: 135-7
37. Hughes BL, Allen DL, Dorato MA, et al. Effect of delivery devices on nasal deposition and mucociliary clearance in rhesus monkeys. Aerosol Sci Technol 1993; 18: 241-9
38. Soane RJ, Frier M, Perkins AC, et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999; 178: 55-65
39. Hallworth GW. Particle size analysis of therapeutic aerosols. In: Morén F, Dolovich MB, Newhouse MT, et al., editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier, 1993: 351-74
40. Thorsson L, Newman SP, Weisz A, et al. Nasal distribution of budesonide inhaled via a powder inhaler. Rhinology 1993; 31: 7-10
41. Digenis GA, Sandefer EP. Acceleration of pharmaceutical research and development with application of gamma scintigraphy. Eur Pharm Contractor 1999; Sep: 22-32
42. Perkins AC, Frier M. Nuclear medicine imaging and drug delivery. Nucl Med Commun 2000; 21: 415-6
43. Le Pape A, Perin F, Diot P. An alternative method to measure the in vivo aerosol deposition: direct labelling of drugs with 99mTc, [abstract]. J Aerosol Med 1997; 10: 92
44. Lafont P, Bellon G, Mein-Tapponnier N, et al. Alpha-1-antitrypsin labelling with technetium-99m for monitoring the deposition of alpha-1 antitrypsin in aerosol therapy. Nucl Med Biol 1998; 25: 509-11
45. Newman SP, Morén F, Clarke SW. The nasal distribution of metered dose inhalers. J Laryngol Otol 1987; 101: 127-32
46. Newman SP, Morén F, Clarke SW. Deposition pattern of nasal sprays in man. Rhinology 1987; 26: 111-20
47. Suman JD, Laube BL, Dalby RN. Comparison of nasal deposition and clearance by aerosol generated by a nebulizer and an aqueous spray pump. Pharm Res 1999; 16: 1648-52
48. Newman SP, Steed KP, Hooper G, et al. Scintigraphic assessment of the oropharyngeal and nasal depositions of fusafungine from a pressurized inhaler and from a novel pump spray device. J Pharm Pharmacol 1995; 47: 818-21
49. Morén F, Bjornek K, Klint T, et al. A comparative distribution study of two procedures for administration of nose drops. Acta Otolaryngol 1988; 106: 286-90
50. Aoki FY, Crawley JCW. Distribution and removal of human serum albumintechnetium 99m instilled intranasally. Br J Clin Pharmacol 1976; 3: 869-78
51. Hardy JG, Lee SW, Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol 1985; 37: 294-7
52. Harris AS, Nilsson IM, Wagner ZG, et al. Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin. J Pharm Sci 1986; 75: 1085-8
53. Bryant ML, Brown P, Gurevich N, et al. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. Nucl Med Commun 1999; 20: 171-4
54. Newman SP, Steed KP, Hardy JG, et al. The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques. J Pharm Pharmacol 1994; 46: 657-60
55. Sandefer EP, Goldberg A, Doll WJ, et al. Rhinoscintigraphy in the assessment of nasal delivery performance in man [abstract]. Pharm Res 1995; 12 Suppl.: S-288
56. Mygind N, Vesterhauge S. Aerosol distribution in the nose. Rhinology 1978; 16: 79-88
57. Washington N, McGlashan JA, Jackson SJ, et al. The effect of nasal patency on the clearance of radiolabeled saline in healthy volunteers. Pharm Res 2000; 17: 733-6
58. Perkins AC, Carney AS, Soane RJ, et al. A dual radionuclide study to assess the effect of the nasal cycle on nasal drug delivery [abstract]. Nucl Med Commun 2000; 21: 374
59. Ridley D, Perkins AC, Washington N, et al. The effect of posture on nasal clearance of bioadhesive starch microspheres. STP Pharma Sci 1995; 5: 442-6
60. Lee SW, Hardy JG, Wilson CG, et al, Nasal sprays and polyps. Nucl Med Commun 1984; 5: 697-703
61. Bond SW, Hardy JG, Wilson CG. Deposition and clearance of nasal sprays. In: Aiache JM, Hirtz J, editors. Proceedings of the 2nd European Congress of Biopharmaceutics and Pharmacokinetics; 1984 Apr 24-27; Salamanca, Spain. Paris: Lavoisier, 1984: 93-8
62. Dewit O, Ball D, Hirst PH, et al. Scintigraphic assessment of nasal deposition and clearance of an aqueous nasal spray administered to healthy volunteers whilst experiencing a common cold [abstract]. Br J Clin Pharmacol 2001; 51: 374P
63. Morén F, Newman SP. Aerosol particles and deposition in the airways. In: Mygind N, Pipkorn U, Dahl R, editors. Rhinitis and asthma: similarities and differences. Copenhagen: Munksgaard, 1990: 258-65
64. Matsune S, Furuta S, Ohyama M, et al. Effective administration of aerosol particles into paranasal sinuses by conservative technique for treatment of sinusitis. Jibi Innkoh-ka Ten-Boh 1997; 40: 201-5
65. Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev 1993; 11: 329-47
66. Okuyama S. The first attempt at radioisotopic evaluation of the integrity of the nose-brain barrier. Life Sci 1997; 60: 1881-4
67. Kern W, Born F, Schreiber H, et al. Central nervous system effects of intranasally administered insulin during euglycaemia in man. Diabetes 1999; 48: 557-63
68. Adams WP, Singh GJP, Williams RL. Nasal inhalation aerosols and metered dose spray pumps: FDA bioequivalence issues. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove (IL): Interpharm Press, 1998: 219-25
69. Suman JD, Laube BL, Ta-chun L, et al. Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition. Pharm, Res 2002; 19: 1-6
70. Chen M-L, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 2002; 18: 1645-50
71. Chang Y, Sandefer EP, Doll WJ, et al. Rhinoscintigraphy to assess bioequivalence of nasal products for non-systemically absorbed drugs [abstract]. Pharm Res 1996 Sep; 13 (9 Suppl.): S-175
72. Data on file, Pharmaceutical Profiles, 2002
73. Meyer R. US regulatory perspective on radiolabelled studies. Presented at the 14th International Congress of the International Society for Aerosols in Medicine; 2003 Jun 14-18; Baltimore
74. Pennington AK, Ratcliffe JH, Wilson CG, et al. The influence of solution viscosity on nasal spray deposition and clearance. Int J Pharm 1988; 43: 221-4
75. Fleming JS, Conway JH. Three-dimensional imaging of aerosol deposition. J Aerosol Med 2001; 14: 147-53
76. Sasajima T, Kinouchi H, Tomura N, et al. High uptake of 123I-metaiodobenzyl-guanidine (MIBG) related to olfactory neuroblastoma revealed by single photon emission CT. AJNR Am J Neuroradiol 2000; 21: 717-20
77. Jones T. New opportunities in molecular imaging using PET. Drug Inf J 1997; 31: 991-5
78. Perkins AC. Nuclear medicine: science and safety. London: John Libbey, 1995
79. Rhodes CG, Hughes JMB. Pulmonary studies using positron emission tomography. Eur Respir J 1995; 8: 1001-17
80. Bergström M, Nordberg A, Lunnell E, et al. Regional deposition of inhaled 11C-nicotine vapour in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 1995; 57: 309-17
81. Berridge MS, Heald DL, Muswick GJ, et al. Biodisvibution and kinetics of nasal C-11 triamcinolone acetonide. J Nucl Med 1998; 39: 1972-7
82. Berridge MS, Lee Z, Leisure GP, et al. Nasal delivery and kinetics of fluticasone propionate using positron tomography. PharmSci 1998; 1: S-208-9
83. Bergström M, Cass LMR, Valind S, et al. Deposition and disposition of [11C] zanamivir as an intranasal spray. Clin Pharmacokinet 1999; 36 Suppl. 1: 33-9
84. Dolovich M, Hahmias C, Coates G. Unleashing the PET: 3D imaging of the lung. In: Dalby RN, Byron PR, Farr SJ, et al., editors, Respiratory drug delivery VII. Raleigh (NC): Serentec Press, 2000: 215-30